Article

Unraveling Cellular and Molecular Mechanisms of Relapse in CD19/CD22 Dual-Targeting CAR T Therapy for B-ALL

2025-10-23

Abstract excerpt

<title>Abstract</title> <p>CD19/CD22 dual-target chimeric antigen receptor (CAR) T cell therapies mark a key advance over single-target options, offering strong potential for patients with refractory B-cell malignancies. Over 20% of patients still experience relapse, and the factors driving this remain less understood. This study evaluated relapse after CAR19/22 T cell therapy in a clinical trial (ChiCTR-OPN-1600...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 52aae8d1-14ee-555c-b6c5-b53e9eee128a
DOI: 10.21203/rs.3.rs-7751632/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Unraveling Cellular and Molecular Mechanisms of Relapse in CD19/CD22 Dual-Targeting CAR T Therapy for B-ALLDOI 10.21203/rs.3.rs-7751632/v1Read

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALLSemantic proximity Read

Tandem CD19/CD22 CAR-T cells conquer high-risk cytogenetics and acquire complete remission in r/r B-ALL patientsSemantic proximity Read

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARSemantic proximity Read

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22Semantic proximity Read

Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALLSemantic proximity Read

CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemiaSemantic proximity Read

Overcoming the challenges of primary resistance and relapse after CAR-T cell therapySemantic proximity Read

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemiaSemantic proximity Read

Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALLSemantic proximity Read

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphomaSemantic proximity Read

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaSemantic proximity Read

Functional diversification and dynamics of CAR-T cells in patients with B-ALLSemantic proximity Read